Alimera科學 ALIM 深 滬
已收盤 09-16 16:00:00 美东时间
5.54
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 5.54
- 總市值 2.90亿
- 52周最高 5.65
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.6063
- 委 比 0.00%
- 總股本 5235.45万
- 歷史最高 131.55
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Altimmune to Participate in Two Upcoming Investor Conferences
Altimmune, Inc. announced that its management team will participate in two investor conferences: the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, and the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025. Both sessions will be available via webcast on the company's Events page.
09-23 11:30
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
Altimmune announced the appointment of Linda M. Richardson as Chief Commercial Officer. Richardson brings over 30 years of experience in sales, marketing, and business development across metabolic, hepatology, and cardiovascular therapeutic areas. Her expertise will support Altimmune's Phase 3 development of pemvidutide for MASH, AUD, ALD, and obesity. Richardson previously held leadership roles at Intercept Pharmaceuticals and Chimerix. Her addi...
09-15 11:30
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune's pemvidutide receives FDA Fast Track designation for treating Alcohol Use Disorder (AUD), addressing a critical unmet medical need. The ongoing Phase 2 RECLAIM trial is evaluating its safety and efficacy in reducing heavy drinking and improving liver health in approximately 100 patients. Pemvidutide, a dual GLP-1/glucagon receptor agonist, shows potential to not only reduce alcohol cravings but also tackle AUD-related comorbidities lik...
08-19 11:30
Altimmune Board of Directors Appoints Jerry Durso as Chairman
Altimmune, Inc. announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025, succeeding Mitchel Sayare, Ph.D., who remains on the Board as an Independent Director. This leadership transition aligns with the Company’s planned advancement into Phase 3 development of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). Altimmune expects to hold an End-of-Phase 2 Meeting with the FDA for M...
08-11 11:30
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
<p>Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, announced it will report its second quarter 2025 financial results on August 12, 2025. Management will host a conference call at 8:30 am E.T. on August 12 to discuss the results and provide a business update. The call will be webcast live on Altimmune’s Investor Relations website. Participants can register here to receive dial-in numbers and a unique PIN. A replay ...
08-05 11:30
Alico, Inc. to Announce Third Quarter 2025 Financial Results on Tuesday, August 12, 2025
Alico, Inc. will release its Q3 2025 financial results on August 12, 2025, after market close. A conference call to discuss the results will be held on August 13, 2025, at 8:30 am ET. U.S. participants can dial 1-800-267-6316, and international participants can dial 1-203-518-9783, using the participant ID "ALICO." A replay will be available from August 13 through August 27, 2025, with U.S. listeners dialing 1-844-512-2921 and international liste...
07-30 20:05
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
The NEW DAY clinical trial compared ILUVIEN® to aflibercept for treating diabetic macular edema (DME) over 18 months. The primary endpoint of the mean number of supplemental aflibercept injections did not reach statistical significance between the ILUVIEN (2.4) and aflibercept (2.5) arms. However, a post-hoc analysis showed ILUVIEN significantly reduced the number of injections (1.8 vs. 2.5, p=0.029). ILUVIEN also met the secondary endpoint, with...
07-23 10:50
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Altimmune, Inc. has enrolled the first patient in the RESTORE Phase 2 trial evaluating pemvidutide for Alcohol-Associated Liver Disease (ALD). Pemvidutide, a GLP-1/glucagon dual receptor agonist, aims to treat ALD, obesity, and metabolic disorders. The trial, led by Dr. Rohit Loomba, will enroll ~100 patients across 34 sites, testing 2.4mg pemvidutide versus placebo over 48 weeks. The primary endpoint is liver stiffness reduction at Week 24, with...
07-09 11:30
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Altimmune Inc. will hold an investor webcast on June 26, 2025, at 8:30 am ET to present 24-week data from its IMPACT Phase 2b trial of pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The call will feature remarks from company management and Dr. Mazen Noureddin, with a replay available on Altimmune’s Investor Relations website. The IMPACT trial enrolled 212 patients with MASH and fibrosis stages F2/F3, evaluating ...
06-25 23:12
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
Altimmune, Inc. will present an oral session and three posters on pemvidutide at the ADA’s 85th Scientific Sessions in Chicago, June 20-23, 2025. Pemvidutide, a GLP-1/glucagon dual receptor agonist, is under development for MASH, obesity, AUD, and ALD. The oral presentation and posters will highlight its effects on cardiometabolic outcomes, including reductions in cardiovascular risk factors, liver fat, and visceral adipose tissue. Detailed findi...
06-13 11:30
